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Abstract
There are two concurrent and novel major research pathways toward strategies for HIV control: (1) long-acting
antiretroviral therapy (ART) formulations and (2) research aimed at conferring sustained ART-free HIV re-
mission, considered a step toward an HIV cure. The importance of perspectives from people living with HIV on
the development of new modalities is high, but data are lacking. We administered an online survey in which
respondents selected their likelihood of participation or nonparticipation in HIV cure/remission research based
on potential risks and perceived benefits of these new modalities. We also tested the correlation between
perceptions of potential risks and benefits with preferences of virologic control strategies and/or responses to
scenario choices, while controlling for respondent characteristics. Of the 282 eligible respondents, 42% would
be willing to switch from oral daily ART to long-acting ART injectables or implantables taken at 6-month
intervals, and 24% to a hypothetical ART-free remission strategy. We found statistically significant gender
differences in perceptions of risk and preferences of HIV control strategies, and possible psychosocial factors
that could mediate willingness to switch to novel HIV treatment or remission options. Our study yielded data on
possible desirable product characteristics for future HIV treatment and remission options. Findings also re-
vealed differences in motivations and preferences across gender and other sociodemographic characteristics that
may be actionable as part of research recruitment efforts. The diversity of participant perspectives reveals the
need to provide a variety of therapeutic options to people living with HIV and to acknowledge their diverse
experiential expertise when developing novel HIV therapies.
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Introduction
The development of oral combined antiretroviral ther-apy (ART) has transformed the HIV epidemic in the
United States and many other countries by allowing people
living with HIV (PLWHIV) to mitigate AIDS-related com-
plications and prevent HIV transmission.1,2 Most PLWHIV
take single-pill combination ART regimens and lead lives
minimally encumbered by HIV-related side effects.3 Several
highly effective classes of ART require daily dosing.4
However, sustained high levels of ART adherence remain a
challenge and do not lead to cure.3,5 Two simultaneous major
advances in HIV therapeutics are occurring: (1) long-acting
(e.g., 1/month) ART formulations, which will soon be
available in clinics across the United States and elsewhere,6
and (2) progress in global research aimed at conferring sus-
tained ART-free HIV remission, with more than 250 ongoing
or completed clinical trials.7,8
Long-acting ART should address some challenges with
daily oral therapy (e.g., pill fatigue and other barriers to
medication adherence).9–11 Possible advantages include the
following: simplified dosing schedules, decreased side ef-
fects, enhanced quality of life, and/or mental well-being.9,10,12
Long-acting ART may also provide advantages to specific
populations (e.g., homeless or unstably housed individuals
and those with mental illness who have difficulty accessing
daily ART). Drawbacks include the need for patients to ad-
here to clinic visits for injections or implants. Two long-acting
intramuscular injectable agents are currently in Phase III drug
development trials, including cabotegravir (CAB) and rilpi-
virine (RPV), which are coadministered monthly or bi-
monthly.6 Long-acting ART could be available in U.S. clinics
as early as 2020.
Products aimed at conferring sustained ART-free HIV
remission are concurrently under early-phase investigation.
These HIV remission research strategies include, but are not
limited to, early ART, immune-based strategies, stem cell
transplantations, gene editing approaches, and latency re-
versing agents. These may be used alone or in combination.5
The aim of these approaches would be to temporarily or
permanently allow PLWHIV to discontinue ART while
maintaining viral suppression. HIV remission studies repre-
sent an inverted scenario from the early days of the HIV
epidemic when PLWHIV joined clinical trials in the hope of
staying alive13–15). Nowadays, PLWHIV are asked to take
risks to advance HIV remission science without expectation
of direct clinical benefits.16,17
The importance of patient perspectives in HIV treatment
and remission development is becoming clearer, as research
on HIV therapies is an increasingly crowded field with newly
emerging and complex product profiles.18 Regulatory agen-
cies such as the U.S. Food and Drug Administration (FDA)
prioritize patient preference in the drug development pro-
cess.19 In 2014, the FDA’s Patient-Focused Drug Develop-
ment Initiative on HIV remission research released the Voice
of the Patient report providing testimonials from PLWHIV
and community advocates on the impact of HIV and its
management.20 Findings from this report could be enhanced
by incorporating scientific evidence on preferences from a
broader community of PLWHIV.21
We previously published data regarding patient willing-
ness to participate and take risks in various types of HIV
remission research in the United States.16,22 Nevertheless, we
know little about the perceptions of PLWHIV regarding
emerging HIV therapies (e.g., long-acting ART or HIV re-
mission strategies). Therefore, we undertook a survey in-
tended to quantify preferences around various HIV treatment
or remission options. We focused on desirable product
characteristics (e.g., acceptable risks or benefits) from the
perspectives of a diverse sample of adults living with HIV in
the United States. The primary survey outcome was respon-
dents’ preferences for virologic control strategies (‘‘HIV
control strategies’’). These HIV control strategies included
oral daily ART versus long-acting ART injectables, or im-
plantables versus a hypothetical ART-free HIV remission
strategy.
We also tested whether the perceived risks and benefits in
HIV remission research differentially influenced participant
willingness. Finally, we examined (1) whether specific
characteristics of HIV treatment and remission options af-
fected likelihood of participating in research and to accept
new regimens and (2) how preferences varied by demo-
graphic and health status characteristics. For consistency, in
the survey we used the term ‘‘treatment’’ to refer to ART,
while we used the National Institutes of Health (NIH)-
endorsed term ‘‘remission’’ to denote research toward an
HIV cure.8 By HIV control strategies, we mean the three
strategies aimed at keeping HIV suppressed—such as con-
tinuous systemic oral ART, continuous systemic long-acting
ART, and non-ART remission.
Methods
From May to August 2018, we administered an online,
nationwide survey via Qualtrics (Provo, UT), using a cross-
sectional design. Survey questions were developed in col-
laboration with community members (D.A., K.M., M.M.,
D.C.) and included extensive review and pilot testing. Due to
funding and institutional review board (IRB) restrictions, the
survey focused on a U.S. sample of PLWHIV. Survey par-
ticipant inclusion criteria were at least 18 years of age, living
with HIV, willing to give their opinion on HIV treatment and
ART-free HIV remission research strategies and remission
options, and living in the United States or its territories. ART
status was not used as an inclusion criterion. Participants had
to check a box certifying they met all eligibility criteria.
There were no stated exclusion criteria. Participants self-
reported their state of residence. While no mechanism was
programmed to prevent survey participation from outside of
the United States, only U.S.-based groups were asked to join
our sampling approach (details below).
We recruited participants via a convenience sample of
PLWHIV who had subscribed to HIV treatment and cure
listservs. These included the following: immune-based ther-
apy, the Martin Delaney Collaboratories Towards an HIV
Cure Community Advisory Boards (MDC CABs), the AIDS
Clinical Trials Group (ACTG), the AIDS Treatment Activists
Coalition (ATAC), The Body, POZ, and the Forum for Col-
laborative Research. In an effort to increase representation of
women and people of color, the survey was also advertised on
listservs hosted by The Well Project and the Positive Women’s
Network-USA (PWN-USA), whose constituencies include
cisgender and transgender women living with HIV in the
United States.22,23 Recruitment posts referenced advancing
social sciences related to HIV treatment and ART-free
remission-related research. To incentivize participation, 1 in
10 participants was randomly chosen to receive a $20 U.S.
Visa gift card. Prospective participants were informed that
they should begin the survey only if they could dedicate time
to complete all the questions in one sitting. All participants
completed an online informed consent form. The survey was
approved by The University of North Carolina at Chapel Hill
Non-Biomedical IRB (study #17–3084).
Measures
Respondent characteristics. The survey included ques-
tions related to demographics, current health status and HIV
medication, opinions and experiences about current HIV
medications, and past participation in HIV research.
Risk aversion versus benefit inclination for participation
in HIV remission studies. Respondents selected their like-
lihood of participation in ART-free HIV remission research
based on 25 specific potential clinical or social risks on a 5-
point Likert scale. Similarly, they rated 16 potential social,
psychological, emotional, or supportive benefits that would
increase their willingness to participate in HIV remission
research on a 5-point Likert scale.
To represent the likelihood of participation in ART-free
HIV remission research, two composite scores were created
based on each respondent’s overall relative risk aversion and
benefit inclination. Composite scores were percentile rank-
ings of each individual’s aggregated responses to the risk and
benefit questions relative to all other survey respondents.
Relative risk aversion was the percentage of all other survey
respondents who had lower risk-averse responses cumulative
over all risk questions (except for two questions related to
childbearing due to gender/sex bias in response). The higher
the relative risk aversion score, the more risk-averse re-
spondents were relative to other survey participants. Relative
benefit inclination was the percentage of all other survey
respondents who had lower benefit-motivated responses cu-
mulative over all benefits questions. The higher the relative
benefit inclination score, the more motivated respondents
were by perceived benefits relative to other survey partici-
pants. Relative risk aversion and relative benefit inclination
were used as key independent variables in the multivariate
regression models.
Perceived improvements over current HIV medica-
tion. Respondents were asked to rate the perceived im-
provement of 12 different potential outcomes of participating
in HIV control strategies over their current HIV medication
strategy on a 5-point Likert scale.
HIV control strategies. For their preferred HIV control
strategy, respondents were asked to make a hypothetical
choice between the following: (1) standard oral daily HIV
medications, (2) long-acting ART injectables or implantables
that last for 1, 2, or 6 months, or (3) a new, less understood
strategy that might keep HIV in remission for an unspecified
‘‘long time.’’ This question was a single categorical variable,
treated as the dependent variable in the bivariate and multi-
variate analyses to test correlations between the mutually
exclusive choices in HIV control strategies and other re-
spondent characteristics. ‘‘I don’t know’’ responses were
recorded in the descriptive summary statistics and removed
from bivariate and multivariate analyses.
Scenario choices. The survey listed seven hypothetical
scenarios with different ART-free HIV remission strategies
having possible negative health consequences in exchange for
no longer having to take oral ART. All scenarios started with
the prompt: ‘‘How likely would you be to choose a new HIV
remission strategy over standard daily HIV medication if.’’
The seven presented scenarios were as follows: (1) no longer
taking daily pills, but having to go to the laboratory or clinic
more often, (2) no longer taking daily pills, but having a small
chance of passing HIV to a sexual partner, (3) taking a new
approach with worse initial side effects that would eventually
fade, (4) a risk of developing health problems (e.g., cancer)
later in life, (5) having to stop taking HIV medications to see if
the virus would come back, (6) no increase in life expectancy,
and (7) no increase in quality of life.
Respondents were asked to choose between the following
5-point Likert scale responses: (1) not at all, (2) somewhat
unlikely, (3) neither likely nor unlikely, (4) moderately
likely, or (5) very likely (to switch to the new HIV remission
strategy) under each scenario. This created an ordinal vari-
able for each scenario and provided the dependent variable in
the bivariate and multivariate analyses testing correlations
between the increased likelihood to switch to a hypothetical
HIV remission strategy and other respondent characteristics.
‘‘I don’t know’’ responses were recorded in the descriptive
summary statistics but were removed from bivariate and
multivariate analyses.
Acceptable trade-offs. Respondents were asked about the
hypothetical acceptability of five different trade-offs to
switching to a new HIV remission strategy, using a Likert-type
response scale. These five trade-offs were as follows: (1)
having injections or infusions every few weeks for several
months before they started working, (2) modest temporary
changes to one’s appearance, (3) enduring mild to moderate
pain, (4) uncertainty about the new strategy working (with the
possibility of having to return to standard HIV medication), and
(5) changes in mental health status (e.g., anxiety or depression).
We provided definitions of all risks, benefits, improve-
ments, strategies, scenario choices, and trade-offs in lay
terms that were vetted by community members (D.A., K.M.,
M.M., D.C.). We randomized many categorical responses to
prevent anchoring effects. Respondents were not required to
answer all survey questions to advance in the survey.
Bivariate analyses
We ran bivariate correlation tests to determine whether
respondent characteristics (e.g., demographics, current health
status and HIV medication, and past participation in HIV
research) were significantly correlated with preference for
HIV control strategy and/or responses to the seven scenario
choices.
HIV control strategies. Logistic models were used to test
and report the odds ratio (OR) of each of the five categorical
choices of HIV control strategies against each of the re-
spondent characteristics.
education. Demographic characteristics of survey respondents
are summarized in Table 1. Due to attrition during the survey,
sample sizes declined from n = 282 for initial questions to
n = 220 for final questions. Therefore, 95% confidence inter-
vals (95% CIs) range from –5.84% to 6.61% for descriptive
survey responses.
Descriptive results and differences by gender/sex
Nearly all survey respondents (99%) were taking ART.
Most respondents (87%) were taking once-daily ART, 12%
reported taking twice-daily ART, and 1% took ART thrice-
daily or more. About 30% reported experiencing side effects
from their HIV medications that did not bother them too
much, while 10% reported side effects from HIV medications
that bothered them a great deal. Over two-thirds (71%) were
grateful to have medications that kept them healthy. Forty-
seven percent reported that taking HIV medications made
them feel in control of their health. Table 2 summarizes re-
spondents’ experiences with current HIV medications.
When asked to assess their own health status on a scale of
0% (poor) to 100% (excellent), 91% of respondents reported
a score ‡50% denoting self-perceived good health. The three
most common reasons for perceived poor health among the
27 respondents with a health status rating below 50% were:
(1) mental health challenges (17/24), (2) ART-related side
effects (14/24), and (3) physical illness not related to HIV
infection (10/24). Of all the survey respondents, 21% had
ever volunteered for an HIV treatment study and 10% had
ever volunteered for an HIV remission study. The most stated
reason respondents did not participate in HIV remission re-
search was not knowing about studies (71%), followed by
transportation issues (16%) and ineligibility (16%) (Table 3).
Risk aversion for participation in HIV remission stud-
ies. The mean relative risk aversion score for all respon-
dents was 42.7 (n = 241, standard deviation [sd] = 22.8). The
minimum was 0 (not at all risk averse) and the maximum was
100 (completely risk averse). The main deterrent to partici-
pation in HIV remission research was a fear of developing
dementia or having difficulty thinking; 63% reported that this
would demotivate them to a great or a very great extent. The
top three clinical risks deterring participation in HIV remis-
sion research were (1) lasting physical pain or discomfort
(55%), (2) developing ART-resistant virus (49%), and (3)
significant changes to one’s immune system (44%). In terms
of perceived social risks, the fear of losing health insurance
was the most prevalent deterrent (57%), followed by the risk
of being treated poorly by study staff (44%), and the risk of
transmitting HIV to a partner during treatment interruption
(41%) (Supplementary Fig. S1).
When data were disaggregated by gender, cisgender and
transgender women were more greatly demotivated by tem-
porary physical pain or discomfort from procedures
( p = .001). Cisgender women were more greatly demotivated
by the need to delay having children ( p = .024) compared
with cisgender men (Fig. 1).
Benefit inclination for participation in remission stud-
ies. The mean relative benefit inclination score was 61.7
(n = 230; sd = 25.6). The minimum was 4.2 (very low moti-
vation) and the maximum was 100 (total motivation).
Scenario choices. Ordered logistic models were used to 
test the bivariate correlations between the ordinal variables 
measuring the 5-point Likert scale responses to the seven HIV 
remission scenarios and respondent characteristics. The OR 
for choosing a higher answer, indicating a greater willingness 
to switch to a new HIV remission strategy, was calculated for 
each scenario and respondent characteristic pairing.
For all bivariate analyses, only statistically significant 
(at the 0.05 level) ORs are reported.
Multivariate analyses
We ran multivariate regression models to test whether 
perceptions of potential risks and benefits were significantly 
correlated with preferences for HIV control strategies and/or 
responses to scenario choices, while controlling for respon-
dent characteristics. Independent variables throughout were 
relative risk aversion and benefit inclination scores and re-
spondent characteristics.
HIV control strategies. We tested associations with the 
categorical dependent variable of preference for HIV control 
strategy. Only a small number of people chose long-acting 
ART taken at 1- or 2-month intervals. Consequently, we 
combined these responses with long-acting ART taken at 6-
month intervals. This combination converted the stated 
preference for HIV control strategy to three mutually ex-
clusive categorical choices: (1) daily oral ART (n = 20), (2) 
long-acting ART injectables or implantables taken at 1-, 2- or
6-month intervals (n = 125), or (3) a new ART-free HIV re-
mission strategy (n = 55). A multinomial logit regression 
model was used to test respondents’ relative risk aversion and 
relative benefit inclination on their stated preferences, con-
trolling for all other variables. We hypothesized that re-
spondents with higher relative risk aversion scores and lower 
relative benefit inclination scores were more likely to choose 
oral daily pills over alternative HIV control strategies.
Scenario choices. We tested associations with ordinal 
dependent variables of the likelihood of being willing to 
switch to a new remission strategy under each of the seven 
scenarios. Ordered logistic regression models were used to 
test respondents’ relative risk aversion and relative benefit 
inclination on greater willingness to switch to a new HIV 
remission strategy under each of the scenarios when con-
trolling for all other variables. We hypothesized that higher 
relative risk aversion scores and lower relative benefit incli-
nation scores would be associated with less willingness to 
switch to a new HIV remission strategy under all scenarios.
All statistical analyses were conducted using Stata (version 
14; StataCorp, College Station, TX).
Results
Survey respondents
In total, 282 eligible respondents completed the survey: 
63% were cisgender men, 35% cisgender women, 1% trans-
gender women, and 1% did not specify a gender. Participants 
were racially and ethnically diverse: 65% were white/Cauca-
sian, 24% black/African American, 4% Asian, 4% multiracial, 
and 3% other, and 12% had Hispanic heritage. Mean partici-
pant age was 47 years, and 86% had at least some college
Primary respondent motivators included the following:
feeling good about helping other people with HIV (78%),
contributing to research (77%), and helping future PLWHIV
(76%). More than three-quarters (78%) of participants would
to a great or very great extent be motivated by direct clinical
benefits. Fifty-one percent of respondents would to a great or
very great extent be motivated by monetary compensation
(Supplementary Fig. S2). When data were disaggregated by
gender, cisgender and transgender women were statistically
significantly more motivated by having regular access to a
study nurse ( p = .039), having someone to speak to about
their HIV status ( p = .001), receiving support from family
and friends ( p < .001), receiving financial compensation
( p < .001), being offered a full meal at the study site
( p = .026), and receiving support for transportation ( p < .001)
(Fig. 2) than cisgender men.
Perceived improvements over current HIV medication. In
terms of desirable characteristics of a potential HIV control
strategy, the three most desired life-changing improvements
were as follows: (1) not having replication-competent HIV
inside the body (83%), (2) no longer taking oral daily ART
(59%), and (3) more confidence in not being able to pass HIV
to others (59%). Categories that would represent no im-
provement pertained mostly to psychosocial factors, includ-
ing (1) not feeling guilt or shame from having HIV (24%), (2)
not feeling stigma from family, partners, or friends (23%),
and (3) not feeling stigma from society (18%) (Supplemen-
tary Fig. S3). When data were disaggregated by gender,
cisgender and transgender women were statistically more
likely to consider not feeling guilt or shame from having HIV
( p = .034) and having a small HIV reservoir size, even
without direct clinical benefit ( p = .015), to be life-changing
improvements, compared with cisgender men (Fig. 3).
HIV control strategies. When given a choice between
HIV control strategies, 9% of respondents would remain on
daily oral ART, 6% would prefer long-acting ART injectable
or implantable taken at 1-month intervals, 7% would prefer
long-acting ART taken at 2-month intervals, 42% would
Table 1. Demographic Characteristics of Survey Respondents (United States, 2018)
n % n %
Gender n = 282 Region of residency n = 272
Cisgender woman 98 35 Northeast 43 16
Cisgender man 179 63 Midwest 32 12
Transgender woman 3 1 South 123 45
Transgender man 0 0 West 74 27
Nonbinary or gender queer 0 0
Something else 1 0.4 Race n = 278
Prefer not to answer 1 0.4 White or Caucasian 182 65
Black or African American 66 24
Sex assigned at birth n = 280 Asian 10 4
Female 96 34 Native Hawaiian or other Pacific Islander 1 0.4
Male 184 66 Native American/Alaska Native 0 0
More than one race 12 4
Age n = 281 Other 7 3
Mean (years) 47
Median (years) 49 Ethnicity n = 271
Minimum (years) 19 Hispanic or Latinx 32 12
Maximum (years) 72 Not Hispanic or Latino/Latina 226 83
Not sure/prefer not to answer 13 5
Age groups (years)
19–29 33 12 Highest level of formal education completed n = 281
30–39 52 19 Some high school, but no diploma 9 3
40–49 62 22 High school diploma or G.E.D. 31 11
50–59 90 32 Some college, but no diploma 84 30
60–72 44 16 2-year college degree 16 6
4-year college degree 77 27
Marital status n = 220 Master’s/professional degree or equivalent 51 18
Single, never married 98 45 Doctorate degree or equivalent 13 5
Separated 4 2
Divorced 34 15 Yearly household income n = 220
Widowed 10 5 Less than $15,000 41 19
Living with a partner 29 13 $15,000–$25,000 28 13
Married, without children 23 10 $25,001–$50,000 56 25
Married, with children 15 7 $50,001–$75,000 24 11
Other 7 3 $75,001–$100,000 18 8
More than $100,000 43 20
Prefer not to answer 10 5
GED, General Education Diploma.
Table 2. Experiences with Current HIV Medication (Oral Daily Antiretroviral
Therapy) (United States, 2018)
n %
Currently taking HIV medication (ART) n = 282
Yes 279 99
No 3 1
Don’t know/not sure 0 0
HIV medication regimen of the 279 respondents taking ART
No. of ART pills or tablets taken per day n = 279
One pill per day 164 59
Two to three pills per day 94 34
Four or more pills per day 21 8
No. of times per day taking ART n = 278
Once per day 243 87
Twice per day 32 12
Three or more times per day 3 1
Interactions with food or other drugs affect timing of ART n = 279
Yes 66 24
No 196 70
Don’t know/not sure 17 6
Feelings about HIV medication n = 279
Very grateful to have medication that is keeping me healthy 198 71
Taking medication makes me feel in control of my health and my life 130 47
Worry that I will not be able to afford or have access to my medication 96 34
Worry that my medication will stop working 68 24
Taking my medication causes me to feel badly about myself or my life 47 17
Side effects from HIV medication n = 276
Have side effects but they don’t bother me too much 82 30
Have side effects and they bother me a great deal 28 10
Trouble taking HIV medication on time n = 215
Have no trouble taking my medication on time every day 194 90
Have trouble remembering to take my medication 23 11
Feeling on trying a completely different kind of HIV medication regimen (ART) n = 278
I would gladly try it 151 54
I would be worried about the side effects 138 50
I would feel anxious about it not working 110 40
ART, antiretroviral therapy.
Table 3. History and Interest in HIV-Related Studies (United States, 2018)
n %
Ever volunteered for a study to test safety or efficacy of an ART drug or related drug n = 278
Yes 57 21
No 216 78
Don’t know 5 2
Ever volunteered for a medical study respondent believed to be an HIV cure study n = 278
Yes 28 10
No 244 88
Don’t know 6 2
Reasons why the 244 respondents did not participate in HIV cure studies n = 243
Did not know about them 173 71
Study site too far away/did not compensate for travel costs 40 16
Did not qualify for them 38 16
Frightened because it would stop HIV medications for some period of time 33 14
Frightened of side effects or negative health effects 24 10
Could not get away from work 16 7
Required too much time away from regular routine 12 5
Regular health provider recommended that I not participate 11 5
Friend or family member said that I shouldn’t participate 4 2
Study did not cover childcare/family care costs involved in participation 1 0.4
Other 23 9
Currently in a study respondent believes to be an HIV cure study n = 278
Yes 9 3
No 266 96
Don’t know 3 1
prefer long-acting ART taken at 6-month intervals, 24% in-
dicated they would prefer a new ART-free HIV remission
strategy about which less is known, and 12% selected ‘‘I
don’t know.’’ When data were disaggregated by gender,
cisgender and transgender women were more willing to
switch a 6-month long-acting ART regimen compared with
cisgender men ( p = .020). Cisgender men were more willing
to try a new ART-free HIV remission strategy compared with
cisgender and transgender women ( p = .033) (Fig. 4).
Scenario choices. In total, 46% of respondents would be
very or moderately willing to switch to an HIV remission
regimen if it meant no more daily ART even with additional
clinic visits for monitoring. This was followed by 45% of
respondents who would switch if the new strategy caused side
effects initially that would improve over time. However, 49%
of respondents would not at all or would be somewhat un-
likely to switch if the HIV remission regimen would increase
the risk for developing health problems later in life (e.g.,
FIG. 1. Extent to which risk factors are ‘‘Likely to Stop’’ respondents from participating in an HIV cure-oriented study,
by gender/sex (United States, 2018). Percentages on the left reflect the sum of ‘‘not at all’’ and ‘‘some extent’’ likelihood to
stop respondent from participating in an HIV cure-oriented study. Percentages on the right reflect the sum of ‘‘very great
extent’’ and ‘‘great extent’’ likelihood to stop respondent from participating in an HIV cure-oriented study. Excludes two
respondents who did not specify their gender. n = 89–91 for cis and trans women. n = 151–155 for cis men. No transgender
men participated in the survey. Asterisks indicate the factors for which the differences in percentages of choosing ‘‘very
great extent’’/‘‘great extent’’ or ‘‘not at all’’/‘‘some extent’’ are statistically significantly different for cis and trans women
than for cis men: **p < .01, *p < .05.
cancer). Furthermore, 59% would not at all or be somewhat
unlikely to switch if there were an increased risk of trans-
mitting HIV to others (Supplementary Fig. S4). When data
were disaggregated by gender, cisgender and transgender
women were less likely to choose the scenarios that would
lead to risks in having health problems later in life ( p = .019),
that would result in worse side effects even if temporary
( p = .006), that are uncertain to work without first stopping
HIV medication ( p = .018), or that might not increase life
expectancy ( p = .046) or quality of life ( p = .032) compared
with cisgender men. Cisgender and transgender women were
more likely to choose a scenario that would mean no more
daily pills but having to visit the clinic more often ( p = .045)
compared with cisgender men (Fig. 5).
Acceptable trade-offs. We asked respondents to indicate
hypothetical acceptability around five possible inconve-
niences, side effects, and unpleasant circumstances of new
HIV treatment or remission regimens. In the aggregate re-
sults, 61% of respondents would only be somewhat bothered
or not at all bothered by having injections/infusions every
other week for several months before the strategy started
working. Fifty-three percent would be willing to undergo
mild to moderate pain. Nevertheless, 56% of respondents
indicated that changes in mental health status as a result of a
new HIV control regimen would be very bothersome or un-
acceptable (Supplementary Fig. S5). When data were dis-
aggregated by gender, cisgender men appeared more willing
to undergo procedures that would cause mild to moderate
pain compared with cisgender and transgender women
( p = .001). Cisgender and transgender women were more
likely to find that having injections/infusions every other
week for several months ( p = .027), pain ( p < .001), and
changes in physical appearance ( p < .001) were unacceptable
or very bothersome trade-offs compared with cisgender men
(Fig. 6).
Bivariate results
HIV control strategies. Using bivariate analyses, we ex-
plored respondent characteristics correlated with choices
between daily HIV medications versus long-acting ART
FIG. 2. Degree by which factors increase respondents’ willingness to participate in an HIV cure-oriented study, by
gender/sex (United States, 2018). Percentages on the left reflect the sum of ‘‘not at all’’ and ‘‘some degree’’ by which
respondent’s willingness to participate in an HIV cure-oriented study would increase. Percentages on the right reflect the
sum of ‘‘very great degree’’ and ‘‘great degree’’ by which respondent’s willingness to participate in an HIV cure-oriented
study would increase. Excludes two respondents who did not specify their gender. n = 85–86 for cis and trans women.
n = 145–146 for cis men. No transgender men participated in the survey. Asterisks indicate the factors for which the
differences in percentages of choosing ‘‘very great degree’’/‘‘great degree’’ or ‘‘not at all’’/‘‘some degree’’ are statistically
significantly different for cis and trans women than for cis men:**p < .01,*p < .05.
versus new ART-free HIV remission. Tables 4 and 5 list the
ORs of results that were statistically significant at the 0.05
level. Cisgender and transgender women were more likely
(OR = 2.0) to prefer switching to a 6-month long-acting ART
regimen but were less likely (OR = 0.5) to prefer a new HIV
remission strategy, compared with cisgender men. Respondents
with postgraduate education, full-time jobs, and/or higher
household income levels were significantly more likely to
prefer a new HIV remission strategy over other options
compared with respondents without those characteristics.
FIG. 3. Improvement over current HIV medication strategy offered by a promising future HIV remission or cure strategy,
by gender/sex (United States, 2018). Percentages on the left reflect ‘‘no improvement.’’ Percentages on the right reflect
‘‘life-changing improvement.’’ Excludes two respondents who did not specify their gender. n = 85 for cis and trans women.
n = 144 for cis men. No transgender men participated in the survey. Asterisks indicate the factors for which the differences in
percentages of choosing ‘‘life-changing improvement’’ or ‘‘ no improvement’’ are statistically significantly different for cis
and trans women than for cis men:*p < .05.
FIG. 4. Choice between current standard daily HIV medications versus long-acting antiretrovirals versus new experi-
mental HIV remission strategy, by gender/sex (United States, 2018). Excludes two respondents who did not specify their
gender. No transgender men participated in the survey. Asterisks indicate the choices for which the differences in per-
centages are statistically significantly different for cis and trans women than for cis men: *p < .05.
FIG. 5. Likelihood of choosing a new HIV remission strategy over standard daily HIV medication under different
scenarios, by gender/sex (United States, 2018). Percentages on the left reflect the sum of ‘‘not at all likely’’ and ‘‘somewhat
unlikely’’ to switch to the new HIV remission strategy. Percentages on the right reflect the sum of ‘‘very likely’’ and
‘‘moderately likely’’ to switch to the new HIV remission strategy. Excludes two respondents who did not specify their
gender. n = 83 for cis and trans women. n = 141–143 for cis men. No transgender men participated in the survey. Asterisks
indicate the remission strategies for which the differences in percentages of choosing ‘‘very likely’’/‘‘moderately likely’’ or
‘‘not at all likely’’/‘‘somewhat unlikely’’ to switch are statistically significantly different for cis and trans women than for
cis men: **p < .01, *p < .05.
FIG. 6. Acceptability of factors under a new HIV remission strategy compared with experiences with standard HIV
medications, by gender/sex (United States, 2018). Percentages on the left reflect the sum of ‘‘unacceptable’’ and ‘‘very
bothered’’ by the factor of the new HIV remission strategy compared with experience with standard HIV medications.
Percentages on the right reflect the sum of ‘‘not bothered’’ and ‘‘somewhat bothered’’ by the factor of the new HIV
remission strategy compared with experience with standard HIV medications. Excludes two respondents who did not
specify their gender. n = 80–81 for cis and trans women. n = 138 for cis men. No transgender men participated in the survey.
Asterisks indicate the remission strategies for which the differences in percentages of choosing ‘‘not bothered’’/‘‘somewhat
bothered’’ or ‘‘unacceptable’’/‘‘very bothered’’ are statistically significantly different for cis and trans women than for cis























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Age, race/ethnicity, partnership status, financial status, time
since first exposure to HIV, time living with HIV, and
current health status were not significantly correlated with
preferred choice of HIV control strategy. Respondents who
were taking ART twice or more frequently per day were more
likely (OR = 3.6–4.0) to choose 1- or 2-month long-acting
ART regimens as their preferred choice of HIV control strat-
egies compared with respondents who took once-daily ART.
Preference for HIV control strategy was not correlated with the
number of ART pills taken daily, whether the timing of ART
was affected by food or other drugs, presence of side effects of
current ART, self-assessed attitude toward trying an alterna-
tive HIV therapy, or previously volunteering for HIV treat-
ment or HIV remission studies.
Scenario choices. We conducted bivariate analyses on
preferences for switching from oral daily ART to new HIV
remission strategies under seven scenarios. Statistically sig-
nificant results are summarized in Tables 6 and 7. Age, part-
nership status, time since first exposure to HIV, time living
with HIV, and health status were not significantly correlated
with increased likelihood of switching to a new HIV remission
strategy in any of the seven scenarios. Under various scenarios
listed in Tables 6 and 7, cisgender and transgender women,
nonwhites/Caucasians, people with higher educational attain-
ment, and people with higher incomes were less willing to
switch to new HIV remission strategies compared with re-
spondents without those characteristics.
Cisgender and transgender women expressed less will-
ingness to switch to new HIV remission strategies if worse
side effects temporarily existed (OR = 0.44), there were in-
creases to their risk of developing health problems later in life
(OR = 0.53), the new remission strategy required treatment
interruption and its success was uncertain (OR = 0.59), or the
new strategy might not increase quality of life (OR = 0.54).
Respondents taking a higher quantity of pills daily expressed
more willingness to switch to a new HIV remission strategy than
to take fewer pills daily, even if the new strategy might increase
the chance of passing HIV to a sexual partner (OR = 4.45) or lead
to health problems later in life (OR = 2.06). Respondents who
felt that daily ART made them feel in control of their lives were
less likely to be willing to switch to a new HIV remission
strategy if it required treatment interruption and if there was
uncertainty in the new strategy working (OR = 0.54).
Respondents who reported anxiety about potential side
effects of a new HIV remission strategy were less likely to be
willing to switch compared with respondents who did not
report being anxious under all seven scenarios (OR = 0.38–
0.61). Conversely, respondents who were willing to try a new
HIV remission strategy to avoid the long-term consequences
of HIV treatment were more likely to be willing to switch to a
new HIV remission strategy even if it would require more
laboratory or clinic visits (OR = 12.29), lead to temporarily
worse side effects (OR = 9.65), lead to health problems later
in life (OR = 3.22), or have uncertainty in the new strategy
working (OR = 2.71), compared with respondents who did
not report willingness to try the new HIV remission strategy
to avoid the consequences of long-term ART.
Supplementary Table S1 provides a summary of bivariate
results for the willingness to switch to a new HIV remission
strategy under the seven scenarios based on past participation
in HIV-related trials and self-assessed willingness to try al-
ternative HIV therapies. Respondents who had participated in
past HIV treatment studies were more likely to be willing to
switch to new HIV remission strategies under nearly all
scenarios (OR = 1.82–2.72).
Multivariate results
HIV control strategies. Results of the multinomial logit
model are presented in Table 8. Respondents who were more
motivated by the potential benefits of HIV remission trials
showed more willingness to switch from daily oral ART to a
new HIV remission strategy or to long-acting ART. Re-
spondents who were more averse to the potential risks of HIV
remission research were less likely to select a new HIV re-
mission strategy over oral daily ART. Each percentage point
increase in the relative benefit inclination score was associ-
ated with an average of 1.07–1.08 in the relative risk ratios of
choosing long-acting ART injectables/implantables or of
choosing a new HIV remission strategy over daily pills, re-
spectively, controlling for various variables listed in the ta-
bles (ceteris paribus). Each percentage point increase in the
relative risk aversion score was associated with a mean rel-
ative risk ratio of 0.93 for choosing a new HIV remission
strategy over daily pills, controlling for other variables. Risk-
averse respondents were also less likely to select long-acting
ART compared with risk-seeking respondents, but the asso-
ciation was not statistically significant at the 0.05 level
( p = .086).
Scenario choices. Results of the seven ordered logistic
models are presented in Table 9. The listed coefficients in-
dicate the ORs of each variable associated with an increased
willingness to switch to the new remission strategy under
each given scenario. Respondents with higher relative benefit
inclination scores were more likely (ORs range 1.01–1.04) to
be willing to switch to remission over oral daily ART under
six of the seven scenarios. There was no statistically signif-
icant association in the scenario where the remission strategy
might not increase life expectancy. Furthermore, respondents
more averse to the potential risks of HIV remission research
were less likely (ORs range 0.96–0.98) to be willing to switch
to a new remission strategy over oral daily ART under all
seven scenarios compared with people with lower relative
risk aversion scores.
Perceptions of specific potential risks, benefits, or im-
provements offered by HIV remission research. Relative
risk ratios of key independent variables that were statistically
significant are summarized in Supplementary Tables S2–S7.
Discussion
Our study provides insights into what adults living with
HIV in the United States perceive as meaningful improve-
ments over oral daily ART, as well as possible desirable
product characteristics for future HIV treatment and remis-
sion options. Our study extends the social sciences literature
on HIV remission research by empirically exploring prefer-
ences for long-acting ART formulations and ART-free HIV
remission strategies versus oral daily ART, as well as pref-
erences for potential product characteristics and acceptable
trade-offs for various HIV therapeutic scenarios. Scholars























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































acceptability of emerging biomedical products to better align
product development with end-user perspectives.24,25 Forward-
looking, patient-centered HIV drug development will necessi-
tate greater knowledge of diverse PLWHIV’s preferences for
novel HIV therapeutic options.11 To that end, an additional
strength of our research is that our sample of PLWHIV showed
more diversity with respect to gender and ethnicity when com-
pared with previous U.S.-based surveys.22,23
An important finding was that 42% of respondents would
be willing to switch from oral daily ART to long-acting
ART injectables or implantables taken at 6-month inter-
vals, corresponding to the biannual frequency of clinic
visits for most PLWHIV in the United States. Currently,
only monthly and bimonthly long-acting formulations have
been studied in clinical research, yet they have shown high
acceptability and satisfaction rates among participants
taking long-acting ART. For example, of the participants
who switched to the long-acting CAB/RPV regimen in the
Antiretroviral Therapy as Long Acting Suppression (AT-
LAS) 48-week study, 97% preferred monthly administra-
tion over previous oral daily ART.26
A separate qualitative study nested in a Phase IIb
CAB/RPV trial conducted in the United States and Spain
found that long-acting injectable ART regimens were highly
desirable from the perspective of PLWHIV because they
reduced internalized stigma, offered convenience, and
peace of mind.9 Furthermore, that study found that the
intermittent dosing of the long-acting ART formulation
would appear to alleviate some of the anxiety associated
with being completely off ART. However, these results
differed from those of a recent study conducted among
racial/ethnic minorities in North and South Carolina, in
which respondents had the least interest in biannual ART
implants. Rather, in that study, PLWHIV expressed great-
est interest in switching to oral ART regimens taken once
weekly (66% very interested), followed by monthly ART
injections (39% very interested) and biannual ART im-
plants (5% very interested).11
Our survey represented a larger U.S. sample of PLWHIV
across multiple states, although our respondents may have
skewed toward those with an interest in advancing HIV
therapies. These discrepant results underscore the importance
of ascertaining potential users’ perspectives in different
populations to ensure that HIV control strategies can meet
diverse patient needs.
Undoubtedly, switching HIV control regimens would be
a critical decision for PLWHIV.20 Decisions to test or try
novel HIV therapies cannot be dissociated from the impact
of HIV on daily life and experiences with current and past
HIV medications.27,28 PLWHIV make careful risk/benefit
calculations based on their perceived health status and
therapeutic options.16 For example, respondents who rated
the potential trade-offs of new HIV remission strategies as
very bothersome were less likely to be willing to choose any
of the new HIV remission strategies than respondents who
did not. Respondents who took ART at least twice daily
were more likely than respondents taking ART once daily to
choose the 1- or 2-month long-acting ART injectable/im-
plantable as their first choice. Furthermore, our multivariate
data reveal that respondents with higher relative risk aver-
sion would be less likely to switch to alternative HIV control
options. Researchers and HIV care providers should pay
close attention to patients’ risk tolerance for being on/off
ART and side effects before proposing a switch to new HIV
therapeutic or research options.
An important concern for PLWHIV is the potential to
transmit HIV to a sexual partner during an analytical treatment
interruption and/or an unsuspected rebound of viremia.16,27 As
noted in our survey, nearly 60% of respondents stated they
would be unlikely to switch to a new HIV remission strategy if
there were a very small increase in the risk that they could
transmit HIV to a partner. This result is consistent with our
previous research, which demonstrated that the fear of trans-
mitting HIV remains one of the most important deterrents for
HIV remission research and interrupting ART.16,27 Relatedly,
59% of survey respondents viewed increased confidence that
they would not pass HIV to others as a significant life-
changing improvement. This finding is important, because the
field of biomedical HIV remission research is shifting toward
less restrictive analytical treatment interruptions and pro-
longed periods of viremia to test promising interventions,
particularly those mediated by the immune system.29
PLWHIV willing to undergo analytical treatment inter-
ruptions may feel a tension between their altruistic desires to
advance HIV remission science and the need to protect their
sexual partners and themselves. We suspect survey respon-
dents’ desire to stay virally suppressed was influenced by the
widespread public health campaign of ‘‘Undetectable =
Untransmittable,’’ which has publicized the scientific evi-
dence associating durable viral suppression (undetectable)
with the lack of HIV sexual transmission (untransmittable).30
Findings also underscore the need to provide adequate pro-
tection measures for sexual partners of those undergoing
analytical treatment interruptions (e.g., appropriate counsel-
ing, PrEP referral or provision, and HIV testing).29
Interestingly, in our study, the most desirable attribute of a
potential HIV remission strategy was the complete elimina-
tion of HIV from the body. This finding is consistent with
focus group results conducted throughout the United States in
which most PLWHIV conceived of a cure/remission as
complete removal of HIV.28,31 In these focus groups, many
PLWHIV did not view ‘‘functional cure’’ as a meaningful
improvement over ART-controlled HIV due to the possibility
of viral rebound.28,31 It will be important to manage com-
munity expectations17 and integrate biomedical research
possibilities with what PLWHIV would find most valuable in
terms of HIV therapy and cure/remission.28
Our study revealed important differences in motivations
and preferences across gender and other sociodemographic
characteristics that may be actionable as part of research re-
cruitment efforts. For example, cisgender and transgender
women were more likely to be motivated by engaging with
research teams, having regular access to a study nurse, being
financially compensated, and receiving support for trans-
portation. Furthermore, cisgender and transgender women
were more likely than cisgender men to choose injectable or
implantable ART lasting at least 6 months above all other
options, consistent with preferences for delivery of contra-
ceptive and HIV PrEP options among women in the United
States and worldwide.32,33 Cisgender and transgender women
were also less likely than cisgender men to choose a new HIV
remission strategy, consistent with our 2015 survey that
showed women were less willing to participate in most types
of HIV remission studies.22 More empirical research will be
community engagement and education, study designs, in-
formed consent, and recruitment efforts. Second, the sample
may have been biased toward respondents with access to
HIV treatment and cure/remission listservs and the Internet.
The sample was likely not representative of PLWHIV in the
United States because individuals without Internet, non-English
speakers, and minors were not included, limiting generaliz-
ability. However, our sample had proportionally more cisgen-
der and transgender women and was racially and ethnically
more diverse than previous U.S. surveys.22,23 Nevertheless, our
sample included a very small number of transgender women,
meaning that aggregate data for women likely reflect the re-
sponses of cis women. Furthermore, characteristics such as age,
gender, HIV status, and location were self-reported, so it is
difficult to confirm the accuracy of the responses. Third, re-
cruitment materials referenced advancing social sciences re-
lated to HIV treatment and cure/remission research; thus, the
sample may have been skewed toward individuals interested in
improving HIV therapeutics and finding an HIV cure. The
complexity of the survey questions may have limited partici-
pants’ full comprehension, although we mitigated this risk by
providing definitions of key concepts in lay terms and having
community members thoroughly review our survey.
We did not assess the entirety of possible product charac-
teristics that could influence patient preferences, such as cost.
The simulated characteristics of HIV treatment and remission
options may not represent actual profiles of therapies or re-
mission strategies that ultimately will be made available to
PLWHIV. We did not assess preferences toward specific HIV
cure/remission strategies, as this was the object of our previous
work.22 We did not ask about factors that would influence
acceptability of analytical treatment interruptions, since the
Treatment Action Group recently published a report on this
topic.38 Instead, this survey focused on desirable product
characteristics from the perspective of adults living with HIV in
the United States. Finally, we did not delve into possible im-
plementation issues related to long-acting ART or HIV re-
mission.
The above limitations notwithstanding, our survey used a
rigorous approach to identify desirable characteristics for
evolving HIV treatment and remission options from the
perspectives of PLWHIV in the United States. Similar re-
search should be conducted in resource-limited settings,
where long-acting ART and HIV remission regimens may
fill a truly unmet need for PLWHIV who do not have access
to daily oral ART regimens. A 2017 systematic review of
national HIV care continua and progress on achieving the
90-90-90 UNAIDS targets revealed that, of the 53 countries
with data, representing *54% of the global estimates of
PLWHIV, the average proportion of PLWHIV on ART was
48%, while only 40% were virally suppressed.39 Thus, the
utility of novel HIV therapies may be greatest in settings
where barriers exist around antiretroviral access and daily
adherence. Survey findings could also be enhanced by
qualitative data collection methods to delve deeper into
reasons behind PLWHIV’s preferences for various options.
More research should also be directed toward what HIV
care providers would perceive as improvements above oral
daily ART.40,41
Table 10 provides a summary of key findings and possible
implications and considerations for HIV treatment and re-
mission research.
needed to ascertain the reasons behind these gender differ-
ences in preferences.
Our survey further revealed possible psychosocial factors 
that could mediate willingness to switch from oral daily ART to 
long-acting ART or HIV remission. The fear of developing 
dementia or having difficulty thinking was the most prevalent 
(63%) deterrent to participation in HIV remission research. 
Possible unacceptable psychosocial risks associated with HIV 
remission research remain largely unexplored in the literature, 
particularly regarding anxiety induced by discontinuing ART 
for a prolonged period. Conversely, psychosocial benefits of 
contributing to HIV remission science were the most significant 
motivators to participation in research, consistent with previous 
sociobehavioral research on HIV remission16,22,34 and the HIV 
prevention and treatment literature.35 Altruistic benefits to 
participation in the context of HIV remission research need to 
be better characterized. It is possible that altruism is mixed with 
the desire for personal benefits, as evidenced by our survey 
findings and similar prior research.20,22
Survey results can inform community engagement, edu-
cation, recruitment, and retention approaches for upcom-
ing long-acting ART implementation and the field of HIV 
remission research. A nuanced understanding of patient 
preference heterogeneity can guide meaningful community 
and stakeholder engagement, enhance patient/participant 
and clinician-research communication, and contribute to 
a more successful and inclusive product development pro-
cess.22 Acceptability research should become a critical 
adjunct to ongoing biomedical research efforts aimed at 
improving long-acting ART regimens, aiming for remis-
sion, and ultimately finding a cure for HIV.25
To make informed decisions around evolving HIV thera-
peutic and research options, PLWHIV may benefit from 
having decision tools and educational materials to better as-
sess possible risks, benefits, and trade-offs.36 For example, 
fact sheets, infographics, instructional videos, HIV treatment 
planners, and reminder systems and pocket cards could be 
created to facilitate future decision-making. More research is 
also needed on how to best support PLWHIV in making de-
cisions around evolving HIV treatment and research options. 
Once PLWHIV begin using long-acting ART injectables or 
implantables, it may be more difficult for them to enroll in 
HIV remission trials involving analytical treatment interrup-
tions due to the prolonged pharmacokinetic trial of ART.
Involvement in HIV remission trials may also mean par-
ticipants will be excluded from future studies if, for instance, 
they develop resistance to the tested interventions. Efforts 
should be made to better understand opportunity costs and 
communicate these to patients/participants. HIV care pro-
viders and biomedical HIV cure/remission researchers also 
need to build trust with PLWHIV to understand their pref-
erences, communicate risks and benefits, and involve them in 
shared decision-making.11,37
Our study has several limitations that must be acknowl-
edged. First, our questions were hypothetical and relied on 
stated preferences. It remains to be seen which choice 
PLWHIV would make if a real-life opportunity presented 
itself to change one’s HIV control options. Switching from 
an oral daily ART regimen to a new ART-free HIV remis-
sion option may be a much bigger leap than switching to 
long-acting ART. Results may not be helpful in predicting 
enrollment or uptake rates; however, responses can inform
Conclusions
Our study attempted to quantify perceived improvements
around emerging HIV therapies and remission strategies
from the perspective of adults living with HIV in the United
States. Respondents ascribed value judgments to specific
benefits, risks, and trade-offs. These should be taken into
account in the drug development process.20 Moving for-
ward, it will be important to pursue HIV therapeutic and
remission research through a mechanism centering on the
needs and perspectives of PLWHIV.42 The high willing-
ness to switch away from daily oral ART may be indicative
of the need for improved therapies; however, the diversity
of patient perspectives reveals that we must be able to
provide a variety of therapeutic options to PLWHIV in the
future. Furthermore, acceptability research should become
a critical component of ongoing biomedical HIV treatment
and remission research efforts.25
More research should be directed toward understanding
evolving community perceptions and unmet needs for
PLWHIV. As PLWHIV become more aware of the avail-
ability of new HIV therapeutic and research options, prefer-
ences may change.11 Ultimately, it will be important to
acknowledge PLWHIV as experiential experts to maximize
the potential benefits they may derive from emerging HIV
therapies and remission strategies.
Table 10. Summary of Findings and Possible Implications for HIV Treatment and Cure/Remission Research
Summary of findings Possible implications
 42% of respondents would be willing to switch from oral
daily ART to long-acting ART injectables or implantables
taken at 6-month intervals.
 24% of respondents who would prefer a new ART-free
HIV remission strategy.
 A variety of therapeutic options should be provided to
PLWHIV in the future.
 Researchers and HIV care providers should attend to
patients’ risk tolerance for being on/off ART and side
effects before propositions to switch to new HIV
therapeutic or research options.
 Decision tools and educational materials for patients may
help them better assess possible risks, benefits, and trade-
offs.
 More research is needed to understand patient preferences
in diverse populations.
 There are important gender differences in perceptions of
risk and preferences of HIV control strategies. For
example, cisgender and transgender women may be less
willing to tolerate risks.
 Gender preferences need to be considered in planning and
implementing HIV treatment and remission research
efforts, particularly to reduce barriers to participation in
research.
 Cisgender and transgender women were also more
motivated by having regular access to a study nurse,
having someone to speak to, receiving support, and
financial compensation for participating in HIV
cure/remission research.
 Desirable life-changing improvements in an HIV control
strategy for PLWHIV would be (1) not having replication-
competent HIV inside the body, (2) no longer taking oral
daily ART, and (3) more confidence in not being able to
pass HIV to others.
 The perspectives and desires of PLWHIV should inform
target product profiles for HIV control and remission
strategies. Behavioral and social sciences research
methods can be used to prioritize strategies that move
forward into human testing.
 Efforts aimed at completely eliminating HIV from the body
should continue alongside efforts to achieve sustained
ART-free HIV remission.
 Community expectations about HIV cure and remission
options should be managed to reduce therapeutic
misconceptions.
 Nearly 60% of respondents stated they would be unlikely
to switch to a new HIV remission strategy if there were a
very small increase in the risk they could transmit HIV to a
partner.
 HIV treatment interruptions can cause relapse in viremia
and increase the possibility of transmitting HIV to sexual
partners. HIV cure/remission research teams should
provide adequate protection measures to sexual partners of
those undergoing analytical treatment interruptions (e.g.,
appropriate counseling, PrEP referral or provision, and
HIV testing).
 59% of survey respondents viewed increased confidence
that they would not pass HIV to others as a significant life-
changing improvement.
 Psychosocial and mental health factors may mediate
willingness to switch to novel HIV treatment or remission
research options. For example, one of the main deterrents
of participating in HIV remission research is the fear of
developing dementia.
 HIV cure/remission research efforts should incorporate
mental health assessments throughout the course of
participation to ensure well-being of study participants.
 There may be neurological impacts of interventions or HIV
treatment interruptions to consider (e.g., viral loads in
cerebrospinal fluid could be assessed to address concerns
such as central nervous system viral escape).
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16. Dubé K, Taylor J, Sylla L, et al.: Well, it’’s the risk of the
unknown . right?’: A qualitative study of perceived risks
and benefits of HIV cure research in the United States.
PLoS One 2017;12:e0170112.
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